Actively Recruiting
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
Led by Xiaotong Hou · Updated on 2026-04-06
154
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
CONDITIONS
Official Title
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Receiving VA-ECMO or VV-ECMO
- Systemic anticoagulation needed with APTT maintained at 40-60 seconds
- Signed informed consent form
You will not qualify if you...
- History of allergy to heparin or bivalirudin
- Previous diagnosis of heparin-induced thrombocytopenia
- ECMO assistance for more than 48 hours before randomization
- Pregnant female
- Prior participation in this study
- Other factors deemed unsuitable by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
X
Xiaotong Hou, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here